Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.54 |
| ▸ | HSD17B3 | P37058 | 13/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26224571 | 0.89 | HSD17B3 (0.44) | NOTUMHSD17B3LMNAKCNN4KCNA3 | |
| SCHEMBL19889885 | 0.88 | HSD17B3 (0.53) | NOTUMHSD17B3 | |
| SCHEMBL19578541 | 0.86 | KDM4E (0.56) | NOTUMHSD17B3LMNAKCNN4KCNA3 | |
| SCHEMBL21604411 | 0.84 | KDM4E (0.41) | NOTUMHSD17B3LMNAKCNN4KCNA3 | |
| SCHEMBL24240781 | 0.80 | NOTUM (0.55) | NOTUMLMNA | |
| SCHEMBL20202310 | 0.80 | TSHR (0.39) | NOTUMLMNA | |
| SCHEMBL25009835 | 0.78 | MTNR1A (0.42) | LMNA | |
| SCHEMBL27349417 | 0.78 | DRD3 (0.38) | — | |
| SCHEMBL25963738 | 0.78 | NOTUM (0.60) | NOTUMHSD17B3 | |
| SCHEMBL23659145 | 0.77 | MAPT (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146902-A1 | METHODS OF PRODUCING HYDROGEL MICROSPHERES | ASCENDIS PHARMA A/S (DK) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023141855-A1 | PROTEIN CONJUGATES WITH MULTIPLE PAYLOADS AND METHODS FOR MAKING THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023141856-A1 | CD3-TARGETING MULTISPECIFIC ANTIBODY AND USE THEREOF | 岩唐生物科技(杭州)有限责任公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023065137-A1 | SITE-SPECIFIC GLYCOPROTEIN CONJUGATES AND METHODS FOR MAKING THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023011639-A1 | OLIGOSACCHARIDE LINKER AND SIDE-CHAIN HYDROPHILIC FRAGMENT COMBINED GLYCOSITE-SPECIFIC ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-02-09 | — | — | WO | disclosed |
| WO-2020112588-A1 | ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020028610-A1 | 2H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-3134128-B1 | SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION | SYNAFFIX BV (NL) | 2019-06-05 | — | — | EP | disclosed |